Your Health, We Care
On March 19, 2024, the FDA accelerated the approval of ponatinib combined with first-line chemotherapy for newly diagnosed adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL).
Ponatinib, as a third-generation Bcr Abl kinase inhibitor, has shown significant efficacy in multiple clinical trials for chronic myeloid leukemia (CML) in resistant or intolerant chronic, accelerated, or acute phases, as well as for Ph+ALL patients.
